Coeptis Therapeutics COEP Stock
Coeptis Therapeutics Price Chart
Coeptis Therapeutics COEP Financial and Trading Overview
| Coeptis Therapeutics stock price | 16.4 USD |
| Previous Close | 0 USD |
| Open | 16.23 USD |
| Bid | 15.86 USD x 100 |
| Ask | 16.45 USD x 100 |
| Day's Range | 15.87 - 17.27 USD |
| 52 Week Range | 6.8 - 21.41 USD |
| Volume | 111.93K USD |
| Avg. Volume | 50.08K USD |
| Market Cap | 102.06M USD |
| Beta (5Y Monthly) | -0.429 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.81 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
COEP Valuation Measures
| Enterprise Value | 96.48M USD |
| Trailing P/E | N/A |
| Forward P/E | -96.47059 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 74.877075 |
| Price/Book (mrq) | 6.9491525 |
| Enterprise Value/Revenue | 70.786 |
| Enterprise Value/EBITDA | -8.134 |
Trading Information
Coeptis Therapeutics Stock Price History
| Beta (5Y Monthly) | -0.429 |
| 52-Week Change | 102.46% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 21.41 USD |
| 52 Week Low | 6.8 USD |
| 50-Day Moving Average | 12.25 USD |
| 200-Day Moving Average | 13.72 USD |
COEP Share Statistics
| Avg. Volume (3 month) | 50.08K USD |
| Avg. Daily Volume (10-Days) | 69.62K USD |
| Shares Outstanding | 6.22M |
| Float | 5.25M |
| Short Ratio | 10.53 |
| % Held by Insiders | N/A |
| % Held by Institutions | N/A |
| Shares Short | 429.8K |
| Short % of Float | 8.00% |
| Short % of Shares Outstanding | 6.90% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | NaN |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -230.64% |
| Gross Margin | 86.74% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -65.054% |
| Return on Equity (ttm) | -136.90% |
Income Statement
| Revenue (ttm) | 1.36M USD |
| Revenue Per Share (ttm) | 0.32 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 1.18M USD |
| EBITDA | -11862286 USD |
| Net Income Avi to Common (ttm) | -11917015 USD |
| Diluted EPS (ttm) | -2.81 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 6.35M USD |
| Total Cash Per Share (mrq) | 1.02 USD |
| Total Debt (mrq) | 268.88K USD |
| Total Debt/Equity (mrq) | 1.91 USD |
| Current Ratio (mrq) | 4.157 |
| Book Value Per Share (mrq) | 2.36 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -8603036 USD |
| Levered Free Cash Flow (ttm) | -3030945 USD |
Profile of Coeptis Therapeutics
| Country | United States |
| State | PA |
| City | Wexford |
| Address | 105 Bradford Rd |
| ZIP | 15090 |
| Phone | (724) 934-6467 |
| Website | https://coeptistx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 4 |
As of April 24, 2026, Coeptis Therapeutics Holdings, Inc. was acquired by Z Squared Inc., in a reverse merger transaction. Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company's product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Q&A For Coeptis Therapeutics Stock
What is a current COEP stock price?
Coeptis Therapeutics COEP stock price today per share is 16.4 USD.
How to purchase Coeptis Therapeutics stock?
You can buy COEP shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Coeptis Therapeutics?
The stock symbol or ticker of Coeptis Therapeutics is COEP.
Which industry does the Coeptis Therapeutics company belong to?
The Coeptis Therapeutics industry is Biotechnology.
How many shares does Coeptis Therapeutics have in circulation?
The max supply of Coeptis Therapeutics shares is 6.22M.
What is Coeptis Therapeutics Price to Earnings Ratio (PE Ratio)?
Coeptis Therapeutics PE Ratio is now.
What was Coeptis Therapeutics earnings per share over the trailing 12 months (TTM)?
Coeptis Therapeutics EPS is -2.81 USD over the trailing 12 months.
Which sector does the Coeptis Therapeutics company belong to?
The Coeptis Therapeutics sector is Healthcare.
Coeptis Therapeutics COEP included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Market Composite NQGM | 2296 USD — |
-1.38
|
— — | 2280.64 USD — | 2323.09 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}